Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical development of mTor inhibitors for renal cancer.
Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S. Ghidini M, et al. Among authors: tomasello g. Expert Opin Investig Drugs. 2017 Nov;26(11):1229-1237. doi: 10.1080/13543784.2017.1384813. Epub 2017 Oct 3. Expert Opin Investig Drugs. 2017. PMID: 28952411 Review.
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
Chiesa MD, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tomasello G, Cocconi G; Italian Oncology Group for Clinical Research. Chiesa MD, et al. Among authors: tomasello g. Acta Biomed. 2007 Dec;78(3):204-9. Acta Biomed. 2007. PMID: 18330080 Clinical Trial.
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Passalacqua R, et al. Among authors: tomasello g. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. doi: 10.1007/s00262-009-0773-9. Epub 2009 Sep 25. Cancer Immunol Immunother. 2010. PMID: 19779715 Free PMC article. Clinical Trial.
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Dalla Chiesa M, Tomasello G, Buti S, Rovere RK, Brighenti M, Lazzarelli S, Donati G, Passalacqua R. Dalla Chiesa M, et al. Among authors: tomasello g. Cancer Chemother Pharmacol. 2011 Jan;67(1):41-8. doi: 10.1007/s00280-010-1281-5. Epub 2010 Mar 5. Cancer Chemother Pharmacol. 2011. PMID: 20204366 Clinical Trial.
Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.
Tomasello G, Liguigli W, Poli R, Lazzarelli S, Brighenti M, Negri F, Curti A, Martinotti M, Olivetti L, Rovatti M, Donati G, Passalacqua R. Tomasello G, et al. Gastric Cancer. 2014 Oct;17(4):711-7. doi: 10.1007/s10120-013-0317-z. Epub 2013 Nov 27. Gastric Cancer. 2014. PMID: 24282019 Clinical Trial.
257 results